Netherlands· NL-e3160a8495aa

Deflazacort XGX Pharma 30 mg tabletten

A deflazacort product containing deflazacort, registered in Netherlands by XGX Pharma ApS. The same ATC class is registered in 8 of our 19 countries.

ATC H02AB13

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about deflazacortAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Deflazacort is registered in 8 of 19 countries.

Countries holding a registration under ATC H02AB13 (deflazacort), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
3 of them publish a price we can compare per daily dose

Search deflazacort products by name

Deflazacort · ATC H02AB13

8 / 19 countries

Denmark
Finlandprice
Germany
Netherlands
Norwayprice
Sweden
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of deflazacort costs, country by country.

Normalised to the WHO defined daily dose (15 mg), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Deflazacort · price per daily dose (15 mg)

USD · FX 28 Sept 2026

ES Spain$0.19

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: DEFLAZACORT
Manufacturer: XGX Pharma ApS
Country: Netherlands (NL)
ATC code: H02AB13
ATC class: Deflazacort
Defined daily dose: 15 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
124419

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

434 interactions on record for deflazacort.

Graded by severity as the source publishes them — 129 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check deflazacort against other medicines How interaction checks work

Deflazacort · interactions on record

434 records

129 severe
297 moderate
8 minor

Most severe, free to view

AprepitantA04AD12severe
LonafarnibA16AX20severe
DesirudinB01AE01severe
BerotralstatB06AC06severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Deflazacort in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All deflazacort products

Authorised across Europe · EMA

The same active substance is authorised in 9 EEA countries. Names it is sold under:

Germany · Calcort, Deflazacort Galen
Denmark · Deflazacort Vital Pharma Nordic
Spain · Defal, Deflazacort Cinfa
Finland · Deflazacort Vital Pharma Nordic
United Kingdom (Northern Ireland) · Calcort
Italy · Decor, Deflan
Norway · Deflazacort Xgx Pharma
Portugal · Deflazacorte Acizan, Deflazacorte Almus
Sweden · Deflazacort

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/cbde25b5-e3d0-49a0-b26a-78ff1a5eae0d
GET /v1/drugs/cbde25b5-e3d0-49a0-b26a-78ff1a5eae0d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h124419_smpc.pdf",
  "strength": null,
  "atc_label": "Deflazacort",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg124419",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MAÏSZETMEEL"
  ],
  "substances": [
    "DEFLAZACORT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h124419.pdf",
  "authorised_at": "2021/11/10",
  "procedure_number": "DK/H/3029/002",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "124419",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about deflazacort.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console